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Abstract  
Introduction: To assess the prevalence of sexual dysfunction in married women with rheumatoid arthritis (RA) and compare it with a control 
group and to determine its association with clinical and disease activity factors. Methods: We conducted a cross-sectional study including sixty 
married women with a confirmed diagnosis of Rheumatoid Arthritis according to the American College of Rheumatology (ACR)/ European League 
against Rheumatism (EULAR) 2010 Criteria, aged 18 or over and having sexual activity. Our controls were healthy volunteers women matched for 
age. Clinical and sociodemographic characteristics were collected. Sexual function was assessed by a self-reported questionnaire the index of 
female sexual function (FSFI). Sociodemographic and disease activity profiles were compared between those who had and did not have sexual 
dysfunction. Results: The prevalence of female sexual dysfunction in women with rheumatoid arthritis attending El Ayachi hospital was 71.9%, it 
was 54% in controls. There was a significant difference in the total FSFI score between patients 18.29±9.09 and controls 23.05±7.91 (p=0.016). 
We found a statistically significant difference between the two groups in almost all dimensions of sexual function (desire, arousal, orgasm, 
satisfaction), except for pain and lubrication. In multivariate analysis, pain assessed by visual analogue scale (VAS) and depression assessed by 
hospital anxiety and depression score (HAD) were the independent determinants of sexual dysfunction. Conclusion: Our study suggests that 
sexual dysfunction is more common among patients with RA compared to controls. These dysfunctions were related to desire, arousal, orgasm and 
satisfaction. Pain and depression appear to be the most important predictors of sexual dysfunction. 
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Introduction 
 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory 
disease leading to significant morbidity and disability [1, 2]. Fatigue, 
pain and decreased joint mobility caused by this rheumatic disorder 
often influence sexual health of patients [3]. RA can affect sexual 
function due to many reasons: Pain, stiffness, physical restrictions 
and fatigue are the major complaints of these patients. They can 
also have problems with body image and self esteem. Their 
medications can also cause sexual problems. Studies on the subject 
are limited and show divergent results [4]. Sexual health is an 
important part of human wellbeing; it has been defined by the 
World Health Organization (WHO) as a state of physical, mental, 
emotional and social well-being in relation to sexuality [5]. Sexual 
function should not be excluded from the monitoring of physical and 
mental health in our daily practice. The definition of female sexual 
dysfunction (FSD) used in clinical research was not uniform before 
the year 2000, where The International Consensus Development 
Conference on Female Sexual Dysfunction defined female sexual 
dysfunction as a persistent or recurring decrease in sexual arousal, 
dyspareunia and difficulty or inability to achieve an orgasm and 
which leads to personal distress and relationship difficulties [6]. 
There are several methods for assessing sexual function; the most 
used on chronic diseases is the FSFI (Female Sexual Function 
Index) which is validated in different countries. The FSFI is a self 
administered questionnaire developed by Rosen in 2000 for 
assessing FSD. It consists of 19 item multidimensional self report 
instruments for assessing the key dimensions of sexual function 
such as: desire, arousal, lubrication, orgasm, satisfaction and pain 
during the last four weeks. This questionnaire is easy to administer 
and is able to differentiate between women with and without sexual 
dysfunction; it has a good discriminative validity, internal 
consistency and test–retest reliability [7]. In our Arabic and Islamic 
culture, discussion about sexuality may be perceived as a taboo 
subject, which may explain the lack of studies in this area [8]. In 
Morocco, there has not been any study about sexual dysfunction 
among RA women. This is the first study looking at the frequency of 
FSD in an RA population using the Moroccan Version of FSFI and 
exploring the relationship between female sexual dysfunction, 









This was a cross sectional, case control study including women with 
a confirmed diagnosis of Rheumatoid Arthritis, aged 18 or over and 
attending El Ayachi University Hospital. The American College of 
Rheumatology (ACR)/ European League against Rheumatism 
(EULAR) 2010 diagnosis criteria was used in this study. All the 
patients were married and had a sexual activity within the last 4 
weeks prior to the time of data collection. Patients were selected 
based on the inclusion and exclusion criteria listed below. A written 
informed consent for participation in the study was obtained from 
participants. We approached 80 patients but we excluded 20. 
  
Inclusion criteria were 
  
Female patients aged 18 years old or over, diagnosed with RA 
according to the ACR/EULAR 2010 criteria and married in a 
heterosexual relationship for the last 6 months. 
  
Exclusion criteria were 
  
Patients known to have other chronic disease, psychiatric illness or 
taking medication that may impair sexual function. Control group 
were healthy married women volunteers matched for age. The 
difficulties of writing and learn were an exclusion criteria. 
  
Measurement tools: primary outcome measure 
  
Female sexual dysfunction (FSD): assessed by Female 
Sexual Function Index (FSFI) 
  
The FSFI is a 19-item multidimensional self-report questionnaire 
assessing sexual dysfunction in the domains of satisfaction, 
lubrication, desire, arousal, orgasm and pain during the previous 
four weeks .The score normally varies between 1.2 and 36. [7]. The 
definition of sexual dysfunction was considered by FSFI as a score 
less than or equal to 26.55 [10, 11]. We used the Moroccan version 
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Rheumatoid Arthritis activity was assessed by DAS 28 ESR score 
(Disease Activity score erythrocyte sedimentation rate). It is 
calculated using a simple formula that measures tenderness and 
swollen joints (28 selected joints), visual analogue scale for patients 
own perception (global health assessment) and ESR. A DAS28 score 
less than 2.6 corresponds to remission ,between 2.6 and 3.2 it 
corresponds to low disease activity , between 3.2 et 5.1 it’s a 





It was evaluated using the Health Assessment Questionnaire (HAQ). 
The questionnaire consists of eight sections: dressing, arising, 
eating, walking, personal hygiene, grip, reach and social activities. 
There are 2 or 3 questions for each section. It explores the 
functional impact of several rheumatic disorders including RA; it 
correlates significantly with disease activity and severity parameters. 
For our local environment, the Moroccan dialect version of HAQ has 
been validated with strong sensitivity, and is valid for assessing 
functional status of RA patients in the Moroccan cultural context 
[13]. 
  
Quality of life Qol: Short Form36 (SF36) 
  
The quality of life QoL was assessed with SF-36 questionnaire, 
which has been previously validated in the Moroccan population 
[14]. It’s a 36 item questionnaire measuring quality of life (Qol) 
across eight domains: physical function, physical role, body pain, 
general health, vitality, social function, emotional role and mental 
health. The scores of the eight domains varies between 0 and 100. 
High scores correspond to less limitations or distress in the different 
dimensions [14]. 
  
Psychological status: Hospital anxiety and depression scale 
HAD 
  
It is a questionnaire commonly used to determine the level of 
anxiety and depression that a patient is experiencing .It is a 
fourteen item scale, where seven questions are related to anxiety 
and seven questions are related to depression Each item is scored 
from 0 to 3, a person can score between 0 and 21 for either anxiety 
or depression .We used the validate Arabic version to detect 




After consent was received, patients answered a sociodemographic 
questionnaire, including age, marital status, educational level and 
professional activity. Disease-specific variables such as date of 
diagnosis of RA, disease duration, history of medication and physical 
examination were recorded. The Moroccan version of FSFI was self-
administered by the patients in a private room to allow privacy. 
Patients were assessed using the DAS28, HAQ, the Visual Analogue 
Scale for Pain and fatigue (VAS), SF36 and HAD scale. All patients 
had routine blood investigations: ESR, C-reactive protein (CRP) 




Data analysis was performed using SPSS for windows version 18. 
Data was expressed as mean ± SD (standard deviation) (for 
normally distributed data) or median (25th, 75th centiles) (for non-
normally distributed data). We divided our patients in 2 groups 
F+(with sexual dysfunction) and F- (without sexual dysfunction) and 
we analyzed the variables between these two groups using the 
independent sample t test (for normally distributed data) , chi 
square (for qualitative data) and the Man -Whitney U-test (for Non-
parametric data).We correlated the FSFI score and its domains to 
the different parameters of the patients and the disease using the 
Spearman test. Multivariate analysis was done for data found to be 
significant in bivariate analysis. Multiple logistic regressions were 
used to analyze predictors for FSD. Factors significant (P < 0.05) in 
unadjusted analyses were included in a logistic regression model to 
determine factors independently associated with sexual impact, with 





Characteristics of patients with RA 
  
Sixty patients who attended El Ayachi hospital were screened, the 
mean of the age of women with RA recruited was 45.18±8.76 
years, forty four (73.3%) had a primary educational level and fifty-
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All patients had established RA, twenty four (40%) of them were 
seropositive .The median of disease duration was 68(37.5-126.6) 
months. The mean of DAS28 ESR was 4.12±1.70 and the median of 




All our patients were assessed using the Moroccan version of FSFI. 
The mean of the score of FSFI among our patients was 18.3±9.1, 
forty six (71.9%) of them had a sexual dysfunction. The median of 
the different domains of FSFI were respectively: Desire 1.5(1.2-3); 
arousal 2.4(1.2-3.6); lubrification 3.15(1.2-3.6); orgasm 3(1.2-4.4); 
satisfaction 3.6(2.4-5.1); pain 5.8(2.17-6).Other characteristics of 
patients and disease are represented in Table 1 and Table 2. 
  
Comparison between women with RA and controls 
  
After comparing our sixty patients and the thirty-one healthy 
volunteer controls for all domains of FSFI, we found a statistically 
significant difference between the two groups in almost all 
dimensions of sexual function (desire(p <0.0001), arousal(p 
=0.004), orgasm(p =0.004), satisfaction(p =0.004)), except for 
pain (p =0.20)and lubrication (p =0.13). 
  
Comparison between RA women with and without sexual 
dysfunction 
  
After Comparison between RA women with (F+) and without (F-) 
sexual dysfunction, we found as shown in Table 3 that: there was 
no significant difference between patients with and without sexual 
dysfunction in term of age (mean of age of patients F+ and F-were 
respectively 45.54±8.89 years and 44±8.53 with P = 0.56).However 
they differed in term of educational level (p =0.033). 
  
Patients with sexual dysfunction had significantly longer duration of 
disease (p = 0.044) and a higher cumulative dose of corticosteroid 
(p=0.015) compared to those without sexual dysfunction. Patients 
with sexual dysfunction reported higher pain expressed by VAS than 
patients without sexual dysfunction (p=0.004) .Disease activity 
measured using DAS28ESR, ESR and CRP level did not differ 
between those with and without sexual dysfunction. 
  
Both patients with (F+) and without (F-) sexual dysfunction had 
similar HAQ scores for assessing disability. There was no difference 
between patients with and without sexual dysfunction in disability 
grading (p=0.081).They differed in term of mental status assessed 
by both HAD (p=0.03) and SF36 score (p=0.006) (Table 3). 
  
Predictors of FSD 
  
In univariate analysis, the determinant factors of sexual dysfunction 
were pain assessed by VAS, anxiety and depression assessed by 
HAD and QOL assessed by physical and mental score of SF36 as 
shown in Table 4and Table 5. In multivariate analysis pain 
assessed by VAS and depression assessed by HAD were the 
independent determinants of sexual dysfunction with respectively 
(Expβ=0.923; CI 95% between 0.866 and 0.998; p=0.043 and 
Expβ=0.698; CI 95% between 0.480 and 1.016; p=0.05). 
  
Correlation between FSFI domains and disease activity, 
functional and psychological status 
  
After examining each FSFI domain score, Age had a negative 
significant correlation with almost all domains of FSFI (Table 6). We 
found also that VAS pain had a significant negative correlation with 
excitation (Spearman’s rho = -0.291, P =0.024), satisfaction 
(Spearman’s rho = -0.366, P = 0.004) and pain (Spearman’s rho = -
0.256, P = 0.049) (Table 6). DAS 28 ESR did not have any 
significant correlation with FSFI scores or its domains except for 
pain. 
  
We found a negative correlation between HAQ score and desire, 
arousal and satisfaction (with respectively Spearman’s rho = -0.353, 
P = 0.007; Spearman’s rho = -0.348, P = 0.008; Spearman’s rho = 
-0.349, P = 0.002). HAD Depression scale had a significant negative 
correlation with FSFI total score and its domains. Almost all domains 
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Discussion 
 
The aim of this study was to explore the prevalence of sexual 
dysfunction in women with RA and to evaluate its association with 
socio-demography, disease activity, functional and psychological 
status. Communication about sexuality is stills a taboo topic in our 
context. Indeed, many patients are reluctant to raise sexual activity 
as well as health professionals. These finding are consistent with a 
previous study in our country [16]. Despite our reserved culture, 
none of our patients refused to participate in this study. 
  
The prevalence of FSD in our sample was respectively 71.9% of 
women with RA and 28.1% of healthy controls. The most affected 
dimensions of sexuality were: lower scores in the domains of desire, 
arousal, orgasm and satisfaction in women with RA than in controls. 
Our results are approximately similar to those found in the literature 
[17-20]. The percentage of RA patients experiencing sexual 
problems ranged in previous studies from 29 to 76% [17,18]. To 
the best of our knowledge, there were few RA studies using FSFI as 
a measure of sexual dysfunction. Shahar and al assessed sexual 
function in women with RA using the FSFI score, they reported a 
lower prevalence of FSD (29.4%) [17]. Similarly, coskun and all 
reported that 68.75% of Turkish women with RA had a sexual 
dysfunction according to FSFI score versus 15% of healthy controls. 
Total score and all domains of FSFI, except of pain were lower in RA 
group versus control group [18]. In Frikha and colleague’s study, 7 
out of 10 women with RA had a sexual dysfunction assessed by 
FSFI score and all subscales of FSFI were affected [19]. Another 
Turkish study found a mean of total score of FSFI in patients with 
RA (22.6 ± 9.0) significantly lower than controls (34.6 ±8.3) [20]. 
In comparison, the prevalence of sexual dysfunction in rheumatic 
disease (including systemic lupus erythematosus; rheumatoid 
arthritis; systemic sclerosis; antiphospholipid antibody syndrome; 
and fibromyalgia) assessed using FSFI was 18.4% [11]. Ayden et al 
reported 54.2% of sexual dysfunction in patients with Fibromyalgia 
versus 15.8% in controls using the FSFI questionnaire [11]. Indeed, 
36 to 70% of all patients with RA are experiencing reduced sexual 
health, and they think that the problem is directly or indirectly due 
to their rheumatoid disorder .Women report more joint difficulties 
than men especially during sexual activities [21]. Two large surveys 
conducted by patient’s organizations in France evaluating 
respectively 7,700 and 1,200 patients with RA who completed the 
questionnaires show that 51% of patients reported an adverse 
impact of this disease on their Sexuality [22], 70% reported a 
negative impact of the disease on their sexuality and 72% reported 
never having discussed their sexuality issues with a health care 
professional [23]. On the other hand, sexual health of patients is 
still rarely evaluated during medical visits [11] even if 56% of RA 
patients think that sexual health is a very important subject [3]. A 
recent study shows that rheumatologists assessed sexual activity in 
only 12% of their patients. the main reason of this negligence were, 
in their opinion, lack of time, difficulty in communication on this 
subject, or thinking that the issue is not related to their field [24]. 
Other reasons explaining this lack of interest in the assessment of 
sexual dysfunction among RA patients is the embarrassment when 
discussing their sexual activity [25]. 
  
In the present study we tried to see if sexual function was affected 
by disease activity, disability, quality of life or psychological status. 
In univariate analysis , we found that pain assessed by VAS, 
psychological status assessed by HAD and Qol assessed by SF36 
were the determinants of sexual dysfunction, but when entered 
simultaneously, only pain and depression seem to be the 
independent factors affecting the sexual function. These findings 
are consistent with previous studies: Yilmaz and al reported that 
pain, disease activity and depression were determined to have a 
negative effect on sexual functions of women with RA [20]. A 
literature review of the sexual health of women with RA found that 
pain, reduced joint mobility, fatigue, depression and body image 
alterations affected sexual health of these patients [26]. Abdel-
Nasser and al found in their regression model that pain, age, and 
depression were the significant determinants for sexual 
dissatisfaction [27]. Indeed, sexual problems are common in 
patients with chronic pain and in those with symptoms of distress 
and depression [28]. In the same way, Helland and colleagues 
found that mental distress was one of the factors independently 
associated with perceived problems with sexual activity [29]. 
  
In the present study, it appears that the level of pain and 
depression play more significant roles compared to disease activity 
or other parameters in contributing to sexual dysfunction in women 
with RA. It should be noted that our study was a cross-sectional 
study, so it was impossible to determine the direction of any 
causality. Our sample was small and taken from a monocentric 
tertiary care setting, therefore, the patients may have more sever 
and active disease. So it’s difficult to generalize the results. 
However, our strong points were that despite our reserved culture, 
we evaluated the sexual function of women with RA using a 
validated questionnaire. 
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Conclusion 
 
Our findings suggest that patients with RA, experience high levels of 
impairment of sexual function (71.9 % of women with sexual 
dysfunction). Factors found to have an independent effect on sexual 
function were pain and depression. Hence, health providers should 
be aware that sexual impairment is an important consequence of 
RA; they must consider sexual function as a part of the assessment 
of disability or quality of life in patients and should guide them by 
providing information or referral to specialists when appropriate. In 
the other hand, a better control of pain and depression symptoms 
may lead us to a better management of sexual life of our patients. 
What is known about this topic 
 Sexual dysfunction is very commun among women with 
Rheumatoid arthritis. 
 There were few RA studies using FSFI as a measure of 
sexual dysfunction. 
 Pain, age and depression seem to be the significant 
determinants for sexual dissatisfaction. 
What this study adds 
 It is the first study looking at the frequency of FSD in an 
RA population using the Moroccan Version of FSFI and 
exploring the relationship between female sexual 
dysfunction, disease activity and socio cultural factors. 
 Sexual dysfunction is frequent among Moroccan married 
women with RA. 
 The most affected dimensions of sexuality in our 
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Table 1: Sociodemographic and disease characteristics of patients with rheumatoid arthritis  
Variable Patients (N=60) 
Age (years) 3 45.18±8.76 
Professional activity1 
  
Without professional activity 53   (88.3%) 
With professional activity 7     (11.7%) 
Educational level1 Primary 44    (73.3%) 
Secondary 14    (23.3%) 
Tertiary 2   (3.3%) 
Menopause1 18 (30%)   




No 2 (3.3%) 
Cumulative dose of steroids (mg)2 9672.5 (3102.2- 20683.33)   
RA treatment1 
  
Methotrexate 50 (83.3%) 
Salazopyrin 25(41.7%) 
Leflunomid 3(5%) 
Biological DMARDS 22(36.7%) 
HAD anxiety3 9.58±4.25   
HAD Depression3 10.73±2.84   
Total score of HAD3 20.13±6.20   
SF36 Domains Physical function3 47.75±21.60 
Limitation due to physical health2 12.74(0-42) 
Pain3 41.92±21.77 
General health3 40.61±16.08 
Energy2 45 (25-50) 
Social function3 45.58±19.16 
Limitation due to emotional problems2 4.02(0-21.26) 
emotional well-being2 40 (29-52) 
RA: rheumatoid arthritis; .had: hospital anxiety and depression score; SF36: short form 36. 
1: number and percentage; 2 median and percentile; 3: mean and standard deviation. 














































Table 2:  Disease characteristics and sexual function of patients 
Variables Patients (N=60) 
VAS pain3 47.83±20.42   
VAS fatigue 3 45.33±20.62   
Number  of tender joint2 5 (2.25-10)   
Number of swollen joint2 1.3 (0.16-4.28)   
ESR2 19   (9-34.75)   
CRP2 5.48 (4.55-15)   
DAS28ESR3 4.12±1.70   
RF2 29 (48.3%)   
ACPA2 24 (40%)   
HAQ2 1 (0.5-1.3)   
FSFI Domains2 Domain1 Desire 1.5(1.2-35) 
Domain2 arousal 2.4(1.2-3.6) 
Domain3 lubrication 3.15(1.2-3.6) 
Domain4  orgasm 3(1.2-4.4) 
Domain5 satisfaction 3.6(2.4-5.1) 
Domain6 pain 5.8(2.17-6) 
Score of FSFI3 18.3±9.1   
Presence of sexual dysfunction1 Patients with sexual dysfunction (F+) 46 (71.9%) 
VAS: visual analogue scale; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; DAS28:Disease Activity 
score; RF: rheumatoid factor; ACPA: anti-citrulinated protein antibodies ; haq: health assessment questionnaire; 
FSFI : female sexual function index 
1: number and percentage; 2 median and percentile;3: mean and standard deviation 














































Table 3: Comparison between patients with (F+) and without (F-) sexual dysfunction 
Variables Patients with sexual  dysfunction 
Patients  without sexual 
dysfunction 
P 
Age3 45±8.89 44±8.53 0.56 
Disease duration(month)2 72(48-132) 27(12-111) 0.044 
Patient with professional activity1 3(42.9%) 4(57.1%) 0.026 
Educational level1                
Primary 35(76.1%) 9(64.3%)   
Secondary 11(23.9%) 3(21.4%) 0.033 
Tertiary 0(0%) 2(14.3%)   
Cumulative dose of steroids2 12600(5475-25550) 36.50(1825-3650) 0.015 
VAS pain3 51.95±18.33 34.28±21.73 0.004 
VAS fatigue3 47.60±20.11 40.71±24 0.12 
ESR2 24(8.75-45) 12(8.75-12) 0.19 
CRP2 6(5-22.5) 5(4-6) 0.079 
DAS28ESR3 4.27±1.77 3.62±1.36 0.21 
HAQ2 1(0.5-1.3) 0.8(0.3-1) 0.081 
HAD ANXIETY3 10.28±4.21 7.28±3.6 0.02 
HAD DEPRESSION3 11.41±2.5 8.5±2.79 <0.00001 
Total score of HAD3 21.17±6.03 16.92±5.78 0.03 
SF36  physical score2 31.87(19.42-39.47) 45.4(32.34-61.83) 0.081 
SF36  mental  score2 30.66(20.06-36.5) 93.93(28.46-49.33) 0.006 
VAS: visual analogue scale; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; DAS28 Disease Activity score; HAQ: health 
assessment questionnaire .had: hospital anxiety and depression score; SF36: short form 36; 1: number and percentage; 2 median and 
percentile; 3: mean and standard deviation 














































Table 4: Sociodemographic and disease activity determinants of sexual dysfunction in univariate and multivariate analysis 
Variable 
Univariate analyis Multivariate analysis 
Exp β CI 95% p Exp β CI 95% P 
Age 0.98 0.919-1.048 0.562 - - - 
Menopause 0.26 0.051-1.342 0.108 - - - 
Educational level 1.523 0.826-2.810 0.178 - - - 
Disease duration 0.991 0.979-1.002 0.107 - - - 
VAS pain 0.954 0.921-0.987 0.008 0.929 0.866-0.998 0.043 
VAS fatigue 0.976 0.946-1,007 0.125 - - - 
Tender joint 0.915 0.8-1.047 0.198 - - - 
ESR 0.971 0.935-1.009 0.131 - - - 
DAS28ESR 0.788 0.539-1.150 0.216 - - - 
Exp: exponential; CI: confidence interval 
VAS: visual analogue scale; ESR: erythrocyte sedimentation rate; DAS28 Disease Activity score 
Table 5: Psychological and Qol determinants of sexual dysfunction 
variable 
Univariate analysis Multivariate analysis 
Exp β CI 95% p Exp β CI 95% P 
HAD anxiety 0.828 0.700-0.978 0.026 - - - 
HAD depression 0.621 0.456-0.846 0.003 0.698 0.48-1.016 0.05 
SF36Physical score 1.035 1.003-1.068 0.029 - - - 
SF36 Mental score 1.063 1.009-1.119 0.021 - - - 
Exp: exponential; CI: confidence interval 
HAD: hospital anxiety and depression score;SF36:short form 36 




























Age -0.425++ -0.532+ -0.313+ 0.466++ -0.467++ -0.402 -0.285+ 
Disease duration -0.258+ -0.164 0.151 -0.348++ -0.246 -0.212 -0.46 
Corticosteroidcumulative 
dose 
-0.339+ -0.181 -0.198 -0.364+ -0.289 -0.343+ -0.199 
VAS  pain -0.347+ -0.227 -0.291+ -0.250 -0.130 -0.366++ -0.256+ 
VAS fatigue -0.295+ -0.159 --0.246 -0.152 -0.183 -0.305+ -0.335++ 
NTJ -0.250 -0.284+ -0.212 -0.131 -0.250 -0.279+ -0.229+ 
NSJ -0.255+ -0.260 -0.195 -0.121 -0.190 -0.284+ -0.290+ 
ESR -0.120 -0.107 -0.032 -0.072 -0.074 -0.068 -0.227 
CRP -0.361+ -0.358+ -0.427++ -0.399+ -0.359+ -0.393+ -0.155 
DAS 28 ESR -0.207 -0.170 -0.158 0.079 -0.144 -0.217 -0.269+ 
HAQ -0.313+ -0.353+ -0.348++ -0.157 -0.198 -0.349++ 0.021 
HAD anxiety -0.336+ -0.189 -0.30++ -0.210 -0.265++ -0.341++ -0.145 
HAD depression -0.521++ -0.284+ -0.459++ -0.444++ -0.408++ -0.530++ -0.276+ 
HAD total score -0.290+ -0.077 -0.265 -0.149 -0.196 -0.324+ -0.254 
SF36  PF 0.488++ 0.448++ 0.432++ 0.406++ 0.367++ 0.494++ 0.340+ 
           LP 0.130 0.21 0.042 0.109 -0.005 0.122 0.128 
B Pain 0.445++ 0.355++ 0.391++ 0.389++ 0.347++ 0.441++ 0.284+ 
GH 0.408++ 0.268+ 0.395++ 0.345++ 0.340++ 0.459++ 0.338++ 
Physical score 0.453++ 0.380++ 0.390++ 0.382++ 0.338++ 0.465++ 0.343++ 
VIT 0.525++ 0.448++ 0.488++ 0.442++ 0.414 0.558++ 0.345++ 
SF 0.456++ 0.456++ 0.407++ 0.361++ 0.310+ 0.40++ 0.283+ 
LE 0.311+ 0.262+ 0.258+ 0.215 0.195 0.313+ 0.149 
MH 0.466++ 0.297+ 0.427++ 0.488++ 0.349++ 0.447++ 0.417++ 
Mental score 0.511++ 0.374++ 0.456 0.485++ 0.370++ 0.477++ 0.410 
+P < 0.05, ++P < 0.001. Significant correlations are marked. Non-significant correlations are not marked 
FSFI :female sexual function index;VAS: visual analogue scale; NTJ: Number of tender joint; .NSJ: number of swollen joint; ESR 
erythrocyte sedimentation rate; CRP: C reactive protein; DAS28 Disease Activity score; haq:health assessment questionaire 
.had:hospital anxiety and depression score;  SF36:short form 36; PF: physical function, LP: physical role, BP: body pain, GH: general 
health, VIT: vitality, SF: social function, LE: emotional role; MH mental health                 
+p<0.05 ++p<0.001 
